Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

336.74 +0.74 (+0.22%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

60 61 Next >

Amgen (AMGN) Reports Earnings Tomorrow: What To Expect

April 30, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect.

Via StockStory

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

The Week Ahead: PCE Inflation Data And Big Tech Earnings In Focus ↗

April 27, 2025

Markets brace for crucial week with Big Tech earnings, Trump's 100-day milestone, and key economic data as trade concerns linger.

Via Talk Markets

Topics Economy Government Stocks / Equities

4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off ↗

April 26, 2025

Via The Motley Fool

Topics Economy Intellectual Property World Trade

Is the Market Bullish or Bearish on Amgen? ↗

April 23, 2025

Via Benzinga

P/E Ratio Insights for Amgen ↗

April 07, 2025

Via Benzinga

1 Value Stock to Research Further and 2 to Ignore

April 24, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold ↗

April 22, 2025

Via The Motley Fool

Topics Government

Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades' ↗

April 22, 2025

Via Benzinga

Short Week Finishes With Netflix Q1 Beat ↗

April 18, 2025

Considering the blue-chip Dow face-planted ahead of the open on a disappointing Q1 report from UnitedHealth, which resulted in a -22% tanking by Thursday’s close, this was a pretty flat day.

Via Talk Markets

Topics Stocks Stocks / Equities

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React ↗

April 17, 2025

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Via Benzinga

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever ↗

April 17, 2025

Via The Motley Fool

Topics Government World Trade

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

April 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...

Via StockStory

Topics Artificial Intelligence

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug ↗

April 14, 2025

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.

Via Benzinga

Topics Intellectual Property Lawsuit

Sandoz Files Antitrust Lawsuit Against Amgen Over Inflammation Drug, Seeks Damages: Retail Sentiment Falters ↗

April 14, 2025

Sandoz is seeking an injunction to prevent Amgen from using patent rights to block biosimilar competition and allow Sandoz to launch its Erelzi “as soon as possible.”

Via Stocktwits

Topics Government Intellectual Property Lawsuit

Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury ↗

April 14, 2025

The company is continuing to test a daily pill that blocks GIPR.

Via Investor's Business Daily

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

Rule Breaker Investing: Essays From Yesterday, Vol. 7 ↗

April 10, 2025

Via The Motley Fool

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

April 09, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market ↗

April 09, 2025

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

Via Benzinga

Topics Government World Trade

3 Dividend Stocks to Buy and Hold for the Next Decade ↗

April 06, 2025

Via The Motley Fool

Topics Economy Intellectual Property

2 Dividend Stocks to Buy Hand Over Fist in April ↗

April 05, 2025

Via The Motley Fool

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks ↗

April 04, 2025

Dip-buying absent in early NY trading, Wall Street deep in red as trade war fears escalate despite strong jobs report. Investors on edge for hints from Fed Chair Powell.

Via Benzinga

Topics Economy Stocks World Trade

FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder ↗

April 04, 2025

The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.

Via Benzinga

Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish ↗

April 04, 2025

Uplizna is now the first FDA-approved treatment for Immunoglobulin G4-related disease, affecting an estimated 20,000 people in the United States

Via Stocktwits

Topics Government World Trade

Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades' ↗

April 04, 2025

Via Benzinga

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday ↗

April 03, 2025

Via The Motley Fool

Topics Economy Government World Trade

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.